Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Evaluating The Efficacy And Safety Of Dose Regimens With Oral CP-690,550 In The Treatment Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT00678210 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00678210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00678210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Evaluating The Efficacy And Safety Of Dose Regimens With Oral CP-690,550 In The Treatment Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2008
Completion date
August 31, 2009
Enrollment
197 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis